Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is labeled “분기보고서” (Quarterly Report) covering 2026-01-01 to 2026-03-31, submitted to the Korean Financial Supervisory Service and Korea Exchange on May 15, 2026. It contains full sections on company overview, financial data, capital changes, and business activities, which are substantive financial statements and analyses for the first quarter. This matches the definition of an Interim/Quarterly Report (IR), not merely an announcement or summary. Q1 2026
2026-05-15 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 90% confidence The document is a formal regulatory notification in Korean regarding corrections (“정정신고”) to a previously filed report on the grant of stock options (“주식매수선택권 부여에 관한 신고”). It details the recipients, share counts, exercise prices and conditions—essentially an announcement of issuing new equity-based instruments (stock options) which changes the company’s capital structure. This aligns with the Share Issue/Capital Change category (Code: SHA).
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 65% confidence The document is a statutory disclosure filed with the Korean Financial Services Commission/Korea Exchange concerning the grant (and correction) of stock options (주식매수선택권 부여에 관한 신고). It is not an earnings release or management commentary, nor a board change announcement. It reports the allocation of rights to subscribe for shares, which relates to capital structure changes. Among our categories, an announcement of issuing new shares or rights that will convert into shares is best classified under Share Issue/Capital Change (SHA).
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a statutory disclosure to the Korean Financial Services Commission and Korea Exchange of a stock‐option (주식매수선택권) grant by the company, detailing the number of options, exercise prices, recipients (directors and employees), conditions, and related adjustments. It is not a brief notice of a report publication or an insider’s personal trade, but a substantive capital‐structure event announcing the issuance of new option rights. This falls squarely under "Share Issue/Capital Change (SHA)".
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 82% confidence The document is a statutory notification to the Financial Services Commission/Korea Exchange concerning the grant (and correction) of stock purchase options (주식매수선택권 부여). It does not contain financial statements or earnings data, nor is it an AGM notice or proxy. It is a corporate disclosure of a capital instrument grant — a change in share-related capital rights. Under our taxonomy, this falls under Share Issue/Capital Change (SHA).
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a statutory notification (“신고”) to the Financial Services Commission/KRX regarding the grant (and subsequent correction) of stock options (주식매수선택권) by the company, including details on grantees, number of shares, exercise price, and related terms. This falls under announcements of new share issuances or capital changes via option grants. Therefore, it should be classified as Share Issue/Capital Change (SHA).
2026-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.